In the late-stage MajesTEC-3 trial, Tecvayli plus the subcutaneous formulation of J&J’s antibody drug Darzalex beat ...
Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years. For nearly 30 years, Dr. Jim Omel has had a front row seat to the ...
Long-term CARTITUDE-1 data show ciltacabtagene autoleucel (cilta-cel) may offer lasting remission and survival in relapsed/refractory multiple myeloma, according to Sundar Jagannath, MBBS, of the ...
Multiple myeloma diagnosis integrates blood tests, genetic assessments, and imaging to guide personalized treatment and patient engagement. Smoldering multiple myeloma involves active surveillance to ...
Bouchard opened a discussion on sequencing therapies in MM, noting that CAR T-cell therapy and bispecific antibodies each ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback